Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2015-08-31
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02163655
Furosemide for Accelerated Recovery of Blood Pressure Postpartum
NCT03556761
Lasix for the Prevention of De Novo Postpartum Hypertension
NCT04752475
Furosemide vs. Placebo for Severe Antepartum Hypertension
NCT04615624
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
NCT04343235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Furosemide/Potassium chloride
40 mg furosemide; 20 meq potassium chloride
Furosemide
40 mg furosemide on postpartum day 1-6
Potassium chloride
20 meq potassium chloride on postpartum day 1-6
Placebo
Placebo #1, Placebo #2
Placebo #1
Placebo (for furosemide)
Placebo #2
Placebo (for KCl)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Furosemide
40 mg furosemide on postpartum day 1-6
Potassium chloride
20 meq potassium chloride on postpartum day 1-6
Placebo #1
Placebo (for furosemide)
Placebo #2
Placebo (for KCl)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Women undergoing vaginal or cesarean delivery at \> 23 weeks gestation with:
* Antepartum diagnosis of gestational hypertension
* Antepartum diagnosis of preeclampsia
* Antepartum diagnosis of preeclampsia with severe features
* Mild hypertension (\<150/100) in first 24 hours following delivery
Exclusion Criteria
* Allergy to furosemide
* Pre-existing hypokalemia (serum K \< 3.0 meq/L)
* Chronic kidney disease
* Serum Cr \> 1.1
* Inability to obtain informed consent
* Pre-existing diuretic use
* Oliguria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Haas
Professor of Obstetrics and Gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Methodius G Tuuli, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Indiana University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University School of Medicine
Indianapolis, Indiana, United States
Washington University School of Medicine
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201501157
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.